Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Textual)

v3.7.0.1
Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 21, 2017
Jun. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
Money Market Funds Fair Value   $ 750,928 $ 750,928 $ 1,500,882
Contingent Consideration Funds Fair Value   1,210,000 1,210,000 $ 1,210,000
Proceeds From Upfront Payment $ 4,000,000      
New Valeant Agreement [Member]        
Revenue Recognition, Milestone Method, Description the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.      
Proceeds From Upfront Payment $ 4,000,000 636,000    
Jade Therapeutics, Inc [Member]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 3,912,314 3,912,314  
Department Of Defence And National Science Foundation [Member]        
Revenue from Grants     $ 221,000